Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

The next four disappointments to come from Navidea will be:

1. A completed 4694 deal that insults the NAVB shareholder and puts lets than $1 million in cash in Navidea's cash starved hands. The sad reality is that the company spent at least $20 million on 4694, so why they hold out now for an extra $100K or $200K is beyond me, unless of course, it is to give the appearance that the company is even worse shape than it is (and help the shorts grip on the stock). Watch and see.

2. Q4 sales will stink out loud. The figure will be under $4 million. The company is notorious for overestimating and overstating sales and revenue expectations. The only sales that are definite are Brent Larson's SALES of every single NAVB share he has before 2016. Watch and see.

3. Manocept will not be spun off until Q1 2017 according to the company and their recent 10Q. This really means it could be 2018, 2019, or NEVER! And the corresponding spinoff shares awarded to NAVB shareholders will be a pittance. Wait and see. Brent Larson is dumping all the NAVB he can. Clearly, he seems to have no interest in the spinoff shares to be doled out at a later date. Watch and see.

4. Lymphoseek sales in Europe will be delayed as long as possible to ram it to the shareholder. Q1 2017? Nah, the company will likely wait much longer than that. The nonsense about premium pricing is just more delay and rhetoric to justify VERY LOUSY SALES IN ADVANCE FOR 2016. Watch and see.